InMed Pharmaceuticals Inc INM

Healthcare Cannabis

InMed Pharmaceuticals Inc. is a pharmaceutical company. It develops a pipeline of small molecule drug candidates targeting the CB1/CB2 receptors. Its InMed Pharmaceuticals segment is engaged in the research and development of small molecule pharmaceuticals drug candidates. Its BayMedica Commercial segment is engaged in the manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Its pharmaceutical pipeline consists of three programs, with drug candidates targeting Alzheimer’s disease, dry age-related macular degeneration, and Epidermolysis Bullosa. Its INM-901 is a drug candidate being developed as a potential treatment for Alzheimer’s disease. Its INM-089 is cannabinoid analog being studied for its potential as a treatment for age-related macular degeneration. Its INM-755 is a cannabinol topical cream which has completed Phase 2 clinical trial studies for the treatment of epidermolysis bullosa.

NDAQ:INM - Post by User

InMed Pharmaceuticals Inc

Bullboard Posts

Comment by RedDeerMoneymanon Feb 16, 2017 10:35pm

118 Views

Post# 25859133

RE:RE:RE:RE:RE:RE:Special Meeting of shareholders 3/24 in Vancouver

Hate to burst the bubble all, but the Computershare letter is automatically generated every year.
No meeting is taking place. Go back and look at every February it's been generated.
When there is a shareholder meeting it's usually in September and all current shareholders will receive information in the mail.

Cheers all

Bullboard Posts

Plurilock scores $5.4 million order with top law enforcement agency